Research Development Foundation is an American private company that operates as noncommercial research organizations.

Thrombogenics, Inc., a subsidiary of Oxurion NV, is a company headquartered in New York, NY. The firm operates as a biotechnology company engages in delivering innovative treatments for diseases of the back of the eye with a focus on diabetic eye disease.

Ventana Medical Systems, Inc., is a world leader and innovator of tissue-based diagnostic solutions for patients worldwide. The company passionately pursues its mission to improve the lives of all patients afflicted with cancer. Ventana Medical Systems discover, develop, and deliver medical diagnostic systems and biopsy based cancer tests that are shaping the future of healthcare. As the leading supplier of cancer diagnostic systems to the pathology market, Ventana manufactures over 220 cancer tests with related instruments right here in southern Arizona for 80 countries, and most importantly, for 4 million people afflicted with cancer yearly around the world. Ventana products provide healthcare professionals with a total solution for all critical steps involved in the analysis of tissue biopsies. This pioneering company also offers premier workflow solutions to improve laboratory efficiency and preserve patient safety. Ventana is committed to accelerating the discovery and development of new cancer tests that allow pathologists to analyze patient samples at the molecular level to help determine the best course of therapy for each individual patient. Ventana enables this with its global leadership as the number one Pharma Industry Partner of Choice in the development and commercialization of companion diagnostics for cancer patients. Ventana Medical Systems is a member of the Roche Group that is drawing on powerful partnerships with world-class scientific institutions.

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

OncoMed Pharmaceuticals, Inc. is a public American pharmaceutical development company headquartered in Redwood City, California. The company was founded in August 2004 by two University of Michigan investigators, Michael Clarke and Max S. Wicha. As of 2013, the company had 83 employees. OncoMed's drug discovery work focuses on developing "targeted antibodies against cancer stem cells". The cancer stem cell technologies on which OncoMed depends are licensed from the University of Michigan where they were developed by the founders of the company. OncoMed went public in 2013 and is listed on NASDAQ under the stock symbol OMED.

KeyGene NV provides its partners and customers in the plant breeding industry contract research, partnerships and molecular genetic services. It delivers novel enabling technologies and applications to support companies and institutes that carry out fundamental or applied genetic genomic research and that seek to enhance the quality of their products through the improvement of their genetic material. The company was established in 1989 and is headquartered in Wageningen, the Netherlands.

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. In 2018, the company's largest selling product lines were Neulasta, an immunostimulator used to prevent infections in patients undergoing cancer chemotherapy and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA.

The University of Iowa Research Foundation (UIRF) - a 501C3 corporation - commercializes University of Iowa developed technologies and inventions through licensing and new venture formation, and manages the subsequent revenue stream.

ARKRAY, Inc. engages in the manufacture and sale of medical and surgical equipment. It develops products that focus on diabetes testing and urinalysis. It also provides the medical testing systems and functional food materials. The company was founded by Tadashi Doi on June 10, 1960 and is headquartered in Kyoto, Japan.

Roche Glycart AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland.

TRION Pharma GmbH is a privately held biopharmaceutical company that has established a novel approach to cancer immunotherapy. The Company’s unique family of trifunctional therapeutic antibodies, called Triomab®, simultaneously activates multiple immune defense mechanisms against cancer. Removab® (catumaxomab), the most advanced candidate of the Triomab® family, received EU market approval for the intraperitoneal treatment of malignant ascites. Removab® is not only the first drug indicated for the treament of malignant ascites, but also the first approved bispecific, trifunctional antibody worldwide. TRION employs about 90 people in Munich for development and cGMP-manufacturing of its antibody products.

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Chongqing Zhongyuan Biotechnology Co., Ltd., established on 2008-04-07, Business scope includes research and development,Production,Sales Ι,II,Class III6840Clinical medical diagnostic reagents,6840Clinical Laboratory Analytical Instruments,In vitro diagnostic reagents(Engage in business according to the items and time limit approved by the license),Sales,Research and development of chemical products and raw materials(Free of Hazardous Chemicals and Class I Precursor Drugs),biotechnology research,to develop,Technical consulting and technology transfer,Import and export,Technology Import and Export(Except for the import and export of goods and technologies that are prohibited by the state or involve administrative approval).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments).

Shanghai Rongsheng Biotech Co., Ltd. principally engages in the research, development, production, and sale of vaccines and in vitro diagnostic reagents. Its products include vaccines, immunodiagnosis reagents, and biochemical diagnosis reagents. The company was founded by Shao Rong Zhu in 1988 and is headquartered in Shanghai, China.

Zhenjiang Jintai Medical Laboratory Co., Ltd., established on 2012-09-05, The scope of business includes laboratory equipment,Instrumentation,Chemical Products(Hazardous chemicals and flammable and explosive materials are excluded),Sales of Class Ι Medical Devices;Health Information Consultation,medical test,Research and development of new biological products,Production,technology transfer,technical consulting.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Wuhan Baide Ruikang Biotechnology Co., Ltd., established on 2013-07-25, Business scope includes biotechnology development,Technical Services,technical consulting;Class II,Production of Class III Medical Devices,Sales;Leasing of medical equipment,repair;Class I medical device,Computer software and hardware sales;Import and export(Does not contain goods prohibited or restricted by the country).(Projects subject to approval by law,Business activities can only be carried out after approval by relevant departments)